Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
SHORT INTEREST
1.64M 08/30/19
P/E Current
-2.07
P/E Ratio (with extraordinary items)
-5.00
Average Recommendation: BUY
Average Target Price: 3.00
SHORT INTEREST
1.64M 08/30/19
P/E Current
-2.07
P/E Ratio (with extraordinary items)
-5.00
Average Recommendation: BUY
Average Target Price: 3.00
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media